H Lee Moffitt Cancer Center and Research Institute H. Lee Moffitt Cancer Center
Welcome,         Profile    Billing    Logout  
 7 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Hyo
NATASHA, NCT05325632: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting
2
53
US
HER-2 pulsed DC1, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Abraxane, Resection surgery
H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration
HER2-positive Breast Cancer
10/25
10/26
MCC-19117, NCT03384914: Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Active, not recruiting
2
119
US
DC1 Vaccine, Immunotherapy, Dendritic Cell Vaccine, WOKVAC Vaccine, pUMVC3-IGFBP2-HER2-IGF1R
H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
12/25
12/27
MCC-18936, NCT03112590: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Completed
1/2
51
US
Interferon-gamma (IFN-γ), Actimmune®, signaling proteins, Paclitaxel, Abraxane®, Trastuzumab, Herceptin®, Pertuzumab, PERJETA®, monoclonal antibody, Post Therapy Surgery
H. Lee Moffitt Cancer Center and Research Institute, Horizon Pharma Ireland, Ltd., Dublin Ireland
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
03/21
02/23
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Dunning, Beverly
No trials found
Carlton, Brooke
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Hyo
NATASHA, NCT05325632: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting
2
53
US
HER-2 pulsed DC1, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Abraxane, Resection surgery
H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration
HER2-positive Breast Cancer
10/25
10/26
MCC-19117, NCT03384914: Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Active, not recruiting
2
119
US
DC1 Vaccine, Immunotherapy, Dendritic Cell Vaccine, WOKVAC Vaccine, pUMVC3-IGFBP2-HER2-IGF1R
H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
12/25
12/27
MCC-18936, NCT03112590: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Completed
1/2
51
US
Interferon-gamma (IFN-γ), Actimmune®, signaling proteins, Paclitaxel, Abraxane®, Trastuzumab, Herceptin®, Pertuzumab, PERJETA®, monoclonal antibody, Post Therapy Surgery
H. Lee Moffitt Cancer Center and Research Institute, Horizon Pharma Ireland, Ltd., Dublin Ireland
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
03/21
02/23
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Dunning, Beverly
No trials found
Carlton, Brooke
No trials found

Download Options